Protocol
Potassium-enriched salt substitute in place of regular salt
Replacing regular salt with a salt substitute that is part potassium chloride lowered stroke, major cardiovascular events and death in a 20,995-person cluster-randomized trial in rural China, lowered cardiovascular events and blood pressure in a second cluster-randomized trial in elderly care facilities, and lowered cardiovascular deaths in an earlier trial in a Taiwanese veterans' home.
At a glance
A salt substitute swaps part of the sodium in salt for potassium. In a very large trial in China, families who cooked with it had fewer strokes, heart attacks and deaths over about five years. Two other trials in care homes found fewer heart and blood vessel events. The extra potassium can be risky for people with kidney disease or on some blood pressure pills. Those people were not tested.
- What was measured
- Strokes, major heart and blood vessel events and deaths over about 4.7 years.
- How big
- Stroke occurred at 29.14 against 33.65 events per 1,000 person-years, that is per 1,000 people per year of follow-up (rate ratio 0.86).Read from the summary of PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 34459569.
- Who it applies to
- Older adults in rural China with prior stroke or high blood pressure, and elderly care residents. Not tested in kidney disease.
- Safety
- Raises blood potassium; people with kidney disease or on potassium-raising drugs were not tested.
- Compared with
- Regular salt.
- Certainty
- Grade A, resting on: Three cluster- or kitchen-randomized trials with hard cardiovascular endpoints The outcome a trial measures to decide whether the treatment worked, such as heart attacks, blood pressure or a symptom score..
- What would change this grade
- Could move down to B if this trial found no benefit: Large randomized trial of potassium-enriched salt substitute outside China, independent of the SSaSS and DECIDE-Salt groups. Who: Older adults with high blood pressure, at least 5,000 per arm. Measured: Stroke and major cardiovascular events. Length: At least 3 years.
- Cost
- No price recorded yet.
- Sources
- 3 studies cited on this record, listed under Sources.
- For clinicians
- A one-page summary of this record that prints with a clinician's name and practice, folds to a plain-language patient handout, and gives a chart note to paste into the patient record: Printable summary and chart note.
Replacing regular salt with a salt substitute that is part potassium chloride lowered stroke, major cardiovascular events and death in a 20,995-person cluster-randomized trial in rural China, lowered cardiovascular events and blood pressure in a second cluster-randomized trial in elderly care facilities, and lowered cardiovascular deaths in an earlier trial in a Taiwanese veterans' home. People with kidney disease or on drugs that raise potassium were not the populations tested.
Why this letter
Why this gradeThe reasoning, and what the grade does not cover.
Grade A on stroke and major cardiovascular events. A cluster-randomized trial of 20,995 people found fewer strokes (rate ratio 0.86), fewer major cardiovascular events (0.87) and fewer deaths (0.88) with a potassium-enriched salt substitute over about 4.7 years (Neal et al., 2021; PMID 34459569), and a second cluster-randomized trial in elderly care facilities found fewer cardiovascular events (HR 0.60) with lower systolic pressure (Yuan et al., 2023; PMID 37055566), and an earlier kitchen-randomized trial in a Taiwanese veterans' home found fewer cardiovascular deaths (Chang et al., 2006; PMID 16762939). The endpoints are hard and objectively counted.
REPLICATION The same finding reproduced by a separate research group. A result seen once can be chance or bias; a replicated one is harder to explain away.the first two trials were run by collaborating academic groups in China and Australia, the third by an independent Taiwanese group; no salt substitute maker is named as funder in their PubMed records.
WHAT THIS GRADE DOES NOT COVERpeople with kidney disease or on potassium-raising drugs; populations outside China; and total mortality in the second trial, which was not significantly lower.
Shared endpoint: Stroke, major cardiovascular events and cardiovascular death
- George Institute for Global Health and Peking University (Neal, Wu): Stroke rate ratio 0.86, major cardiovascular events 0.87, death 0.88, 20,995 people, 4.74 years. PMID 34459569 · Funding: National Health and Medical Research Council of Australia
- Peking University Clinical Research Institute and the George Institute (Yuan, Wu): Cardiovascular events HR 0.60, systolic pressure 7.1 mmHg lower, 1,612 residents, 2 years. PMID 37055566 · Funding: academic; no commercial funder named in the indexed record
- Taiwanese veterans' home investigators (Chang): Cardiovascular deaths 13.1 against 20.5 per 1,000 person-years, 1,981 veterans, about 31 months. PMID 16762939 · Funding: academic; no commercial funder named in the indexed record
A grade describes the human evidence for a named use. It is not advice, and it is not a judgment on any individual prescription. How the letters are decided →
Who responds: this record's trial reading reports no subgroup that identifies who responds.
ClinicalTrials.gov, the public registry run by the U.S. National Library of Medicine, lists studies that are recruiting volunteers. The link below searches it for Salt Substitute among studies recruiting now. EBL has no relationship with any listed study and receives no payment for this link.
Search recruiting studies of Salt Substitute on ClinicalTrials.gov
Evidence notes: randomized trial
Endpoint graded: Stroke, major cardiovascular events and death (hard)
Last reviewed: November 2026
Dose, form and timing
Blood pressure, and serum potassium in anyone with kidney disease or taking drugs that raise potassium (such as ACE inhibitors, ARBs, spironolactone or potassium supplements), who were not the populations tested.
As studiedDose, form, population and duration for every use.
A grade describes the intervention that was tested. Where the product on the shelf differs from it, this says so.
Safety
No human harm data, with cautions for groups never studied. Each caution on this record, sorted by what it rests on.
None recorded.
None recorded.
None recorded.
- People with kidney disease or on potassium-raising drugs (ACE inhibitors, ARBs, potassium-sparing diuretics) were not tested
No safety data: EBL has found no trial or report of harm for this record. That is an absence of evidence, not a finding of safety.
Grade history
How this letter has changedLatest: No. 439 · November 2026 · First graded.
New record in the food section. Replacing regular salt with a salt substitute that is part potassium chloride lowered stroke, major cardiovascular events and death in a 20,995-person cluster-randomized trial in rural China, lowered cardiovascular events and blood pressure in a second cluster-randomized trial in elderly care facilities, and lowered cardiovascular deaths in an earlier trial in a Taiwanese veterans' home. People with kidney disease or on drugs that raise potassium were not the populations tested.PMID 34459569 PMID 37055566 PMID 16762939
Every change to a letter on this site is dated and published. The full evidence log →
Sources
- Citations
- Every paper cited on this page is matched to its PubMed record on every build.
- Retractions
- None of these papers is retracted or under a journal expression of concern. PubMed is checked again on every build.
- Read against the papers
- November 2026. By a language model (AI-assisted reading), not yet reviewed by a clinician.
- Outside review
- Not yet done. No reviewer outside EBL has checked this record.
What each of these checks can and cannot show: evidence integrity.
The evidence, in fullThree papers, each linked to its PubMed record.
Neal et al. (N Engl J Med, 2021; PMID 34459569): SSaSS, open-label Everyone in the trial knows which treatment they are receiving, so expectations can shape the results, especially for symptoms people report themselves. cluster-randomized trial in 600 villages, 20,995 people with prior stroke or age 60 or older with high blood pressure, mean follow-up 4.74 years; salt substitute (75% sodium chloride, 25% potassium chloride) against regular salt; stroke rate ratio 0.86 (95% CI 0.77 to 0.96), major cardiovascular events 0.87, death 0.88; serious hyperkalemia not higher. Yuan et al. (Nat Med, 2023; PMID 37055566): DECIDE-Salt, 48 elderly care facilities, 1,612 people aged 55 or older, 2 years; salt substitute (62.5% sodium chloride, 25% potassium chloride) lowered systolic pressure 7.1 mmHg and cardiovascular events (HR 0.60, 95% CI 0.38 to 0.96); total mortality not significantly lower; biochemical hyperkalemia more frequent without adverse clinical outcomes. Chang et al. (Am J Clin Nutr, 2006; PMID 16762939): five kitchens of a Taiwanese veterans' retirement home randomized to potassium-enriched or regular salt for about 31 months, 1,981 veterans; cardiovascular deaths 13.1 against 20.5 per 1,000 person-years.
How EBL searched for the trials (1 search)
The search that was run, what it returned, and what was left out and why, so the absence of evidence can be checked as well as its presence.
("salt substitute*"[tiab] OR "potassium-enriched salt"[tiab]) AND randomized controlled trial[pt]PubMed watch: does a new study change the grade? (nothing new)
No new paper matching the search behind this grade has been added to PubMed since November 2026.
Last run November 2026. A letter on EBL moves only after a logged review. A new paper never moves a letter by arriving: it is read, the answer is written here, and any change to the letter is published in the evidence log.
For each trial behind a letter on this page, the funding its PubMed record lists. "No funder" means PubMed lists none, not that the trial had no funding.
- Neal et al., 2021, N Engl J Med (PMID 34459569): PubMed lists funding from National Health and Medical Research Council of Australia; Medical Research Council; National Health and Medical Research Council.
- Yuan et al., 2023, Nat Med (PMID 37055566): PubMed lists funding from Medical Research Council.
- Chang et al., 2006, Am J Clin Nutr (PMID 16762939): PubMed lists no funder for this trial.
Disclosure
Educational use only · Not medical advice · EBL grades published human evidence and does not recommend treatment. Stopping a prescription is a decision for your physician.
Evidence Based Longevity, Inc. is owner-operated and edited by Arnold Sandlow, D.C., a California-licensed chiropractor. Evidence Based Longevity publishes in English only · Machine translations are not produced or reviewed by EBL for accuracy
© Evidence Based Longevity, Inc. All rights reserved
These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.
Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →